Validation of Indonesian Graves’ Ophthalmopathy Quality of Life Questionnaire and Its Association with Clinical Activity and Severity of Graves’ Ophthalmopathy
Abstract
Background: Graves’ ophthalmopathy (GO) ocular abnormalities can persist even after treatment, negatively impacting patients’ psychological and social health. The Indonesian Graves’ Ophthalmopathy Quality of Life (GO-QoL) Questionnaire has not been validated, hence it cannot measure patient quality of life, which is crucial to GO treatment. We aimed to provide a reliable Indonesian GO-QoL Questionnaire and identify an association between patient quality of life and clinical activity and the severity of GO. Methods: The process of questionnaire validation involves transcultural adaptation and a cross-sectional design. The content validity index (CVI) and Cronbach’s alpha assessed validity and reliability, respectively. Results: The CVI was 1.00 for the Indonesian GO-QoL questionnaire. The Cronbach’s alpha for the visual function subscale value was 0.971, the appearance subscale value was 0.993, and the total score was 0.986. The appearance subscale and total score of GO patients’ quality of life had a significant association with clinical activity score (p<0.05) and disease severity (p<0.001). Conclusion: The Indonesian version of the GO-QoL has good validity and reliability. Both the active clinical activity of GO and the severity of the disease decreased patients’ appearance and general quality of life.
Keywords
References
Perros P, Hegedüs L, Bartalena L, et al. Graves’ orbitopathy as a rare disease in Europe: a European Group on Graves’ Orbitopathy (EUGOGO) position statement. Orphanet Journal of Rare Diseases. 2017;12:72.
Sadaka A, Nguyen K, Malik A, Brito R, Berry S, Lee AG. Vitamin D and selenium in a thyroid eye disease population in Texas. Neuro-ophthalmology (Aeolus Press). 2019;43:291–4.
Scott R. The ocular trauma acore. Community Eye Health. 2015;28:44–5.
Estcourt S, Quinn AG, Vaidya B. Quality of life in thyroid eye disease: impact of quality of care. European Journal of Endocrinology. 164:649–55.
Bartalena L, Fatourechi V. Extrathyroidal manifestations of Graves’ disease: a 2014 update. Journal of Endocrinological Investigation. 2014;37:691–700.
Villagelin D, Romaldini J, Andrade J, et al. Evaluation of quality of life in the Brazilian Graves’ disease population: Focus on mild and moderate graves’ orbitopathy patients. Frontiers in Endocrinology [Internet]. 2019:192.
Wild D, Grove A, Martin M, Eremenco S, McElroy S. Principles of good practice for the translation and cultural adaptation process for patient-reported outcomes (PRO) measures: report of the ISPOR task force for translation and cultural adaptation. Value Health. 2005;8:94–104.
Lumyongsatien M, Keeratidamkerngsakul B, Pornpanich K, et al. Development and psychometric properties of the Thai Graves’ ophthalmopathy quality of life (GO-QOL) questionnaire. Journal of Patient-Reported Outcomes. 2019;4:1.
Zeng P, Fan S, Li Z, et al. Vitamin D and selenium in a thyroid eye disease population in Texas. Neuro-ophthalmology (Aeolus Press). 2019;43:291–4.
Perros P, Hegedüs L, Bartalena L, et al. Graves’ orbitopathy as a rare disease in Europe: a European Group on Graves’ Orbitopathy (EUGOGO) position statement. Orphanet Journal of Rare Diseases. 2017;12:72.
Estcourt S, Quinn AG, Vaidya B. Quality of life in thyroid eye disease: impact of quality of care. European Journal of Endocrinology. 164:649–55.
Bartalena L, Fatourechi V. Extrathyroidal manifestations of Graves’ disease: a 2014 update. Journal of Endocrinological Investigation. 2014;37:691–700.
Sawicka-Gutaj N, Bednarczuk T, Daroszewski J, et al. GO-QOL — disease-specific quality of life questionnaire in Graves’ orbitopathy. Endokrynologia Polska. 2015;66:362–6.
Lumyongsatien M, Keeratidamkerngsakul B, Pornpanich K, et al. Development and psychometric properties of the Thai Graves’ ophthalmopathy quality of life (GO-QOL) questionnaire. Journal of Patient-Reported Outcomes. 2019;4:1.
Stan MN, Bahn RS. Risk factors for development or deterioration of Graves’ ophthalmopathy. Thyroid. 2010;20:777–83.
Delampady K, Reddy S, Yadav S. Assessing the quality of life in Indian Graves’ orbitopathy patients and validation of Hindi version of GO-QOL questionnaire. Indian Journal of Ophthalmology. 2020;68:1617.
Delfino L, Zunino A, Sapia V, Croome M, Ilera V, Gauna A. Related quality of life questionnaire specific to dysthyroid ophthalmopathy evaluated in a population of patients with Graves’ disease. Archives of Endocrinology and Metabolism. 2017;61.
Zeng P, Fan S, Li Z, et al. Evaluation of the Graves’ orbitopathy-specific quality of life questionnaire in the mainland Chinese population. Journal of Ophthalmology. 2019;2019:7602419.
Terwee C, Dekker F, Mourits MP, et al. Interpretation and validity of changes in scores on the Graves’ Ophthalmopathy quality of life questionnaire (GO-QOL) after different treatments. Clinical Endocrinology. 2001;54:391–8.
Choi YJ, Lim HT, Lee SJ, Lee SY, Yoon JS. Assessing Graves’ ophthalmopathy-specific quality of life in Korean patients. Eye (London, England). 2012;26:544–51.
Villagelin D, Romaldini J, Andrade J, et al. Evaluation of quality of life in the Brazilian Graves’ disease population: Focus on mild and moderate Graves’ orbitopathy patients. Frontiers in Endocrinology. 2019;192.
Roopa S, Menta Satya R. Questionnaire designing for a survey. The Journal of Indian Orthodontic Society. 2012;46:37–41.
Hoppe E, Lee ACH, Hoppe D, Kahaly GJ. Predictive factors for changes in quality of life after steroid treatment for active moderate-to-severe Graves’ orbitopathy: A prospective trial. European Thyroid Journal. 2020;9:313–20.
Subekti I, Soewondo P, Soebardi S, Darmowidjojo B, Harbuwono D, Purnamasari D. Practical guidelines management of Graves ophthalmopathy. Acta Med Indones. 2019;4:364–71.
Refbacks
- There are currently no refbacks.
This work is licensed under a